Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Firms Fight Against 'Whisper Campaign' On Interchangeability

Executive Summary

Industry calls for more education amid concerns that brand sales reps are encouraging providers to use only interchangeable products because they are better than biosimilars.


Related Content

Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts
Humira Biosimilar: Boehringer Faces Same Launch Hurdles As Amgen
Humira Biosimilar Interchangeability: The Race Begins
US Comparator Requirement For Interchangeable Biosimilars Would Hurt Industry
Biosimilars: Postmarketing Data Alone Not Enough For Interchangeability
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
Biosimilar Interchangeability May Be Losing Luster As Approval Goal
Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?
Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action
FDA Biosimilar Education Campaign Will Need To Be Targeted


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts